GPC3 and hepatocellular carcinoma: The phase I/II ATHENA (NCT06084884) single-arm trial to evaluate the safety, cellular kinetics, and efficacy of AZD5851, a CAR-T therapy directed against glypican-3, as the second-line or beyond treatment of patients with advanced HCC is ongoing [Table 5].